Professor John Walsh in San Francisco: Lancet controlled clinical trial for CoronaVac, the Chinese vaccine most often used.
Peer reviewed in an internationally recognized journal, one of the world’s best:
“In the per protocol population (n=10 029), 41 cases of symptomatic COVID-19 occurred at least 14 days after the second dose of vaccine or placebo (91·1 cases [66·2–121·6] per 1000 person-years). Of these cases, nine were reported in the vaccine group (n=6559; 31·7 cases [14·6–59·3] per 1000 person-years) and 32 in the placebo group (n=3470; 192·3 cases [135·7–261·1] per 1000 person-years), yielding a vaccine efficacy of 83·5% (95% CI 65·4–92·1; p<0·0001) for the prevention of PCR-confirmed symptomatic COVID-19.
“Cumulative incidences of COVID-19-related events in the vaccine and placebo groups are shown in figure 2. There were no fatal cases of COVID-19. Hospitalisation was recorded in none of the participants in the vaccine group and six in the placebo group (36·4 hospitalisations [13·5–77·5] per 1000 person-years), giving a vaccine efficacy of 100% (20·4–100·0; p=0·0344) for the prevention of COVID-19-related hospitalisation.”
Looks very good!!!
Sinopharm the other major Chinese vaccine in use appears to be even better. But it is unclear which variants were encountered in this population in Turkey.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext
Johnson Choi Biz 